{"id":60412,"date":"2024-02-28T06:47:45","date_gmt":"2024-02-28T06:47:45","guid":{"rendered":"https:\/\/medsname.com\/rasalect\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rasalect","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/rasalect\/","title":{"rendered":"Rasalect"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Rasalect<\/strong> je peror\u00e1ln\u00ed rasagiline<\/strong> (1 mg) tableta \u2014 selektivn\u00ed inhibitor monoaminooxid\u00e1zy typu B (MAO-B)<\/strong> pou\u017e\u00edvan\u00e1 k l\u00e9\u010db\u011b Parkinsonova choroba<\/strong>. Blokov\u00e1n\u00edm MAO-B v mozku zpomaluje rozklad dopaminu a pom\u00e1h\u00e1 prodlou\u017eit dobu, po kterou levodopa \u00fa\u010dinkuje mezi d\u00e1vkami (sni\u017euje \u201coff\u201d \u010das). Na rozd\u00edl od selegilinu rasagiline ne<\/em> se nemetabolizuje na amfetaminov\u00e9 deriv\u00e1ty, tak\u017ee nespavost je mnohem men\u0161\u00edm probl\u00e9mem. \u010cast\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky: nespavost, bolest hlavy, dyskineze, sucho v \u00fastech, ortostatick\u00e1 hypotenze. D\u016fle\u017eit\u00e9:<\/strong> Vyhn\u011bte se kombinaci s v\u011bt\u0161inou antidepresiv (SSRI, SNRI, TCA), opioidy, jako je pethidine a tramadol, a dextromethorphanem \u2014 riziko serotoninov\u00fd syndrom<\/em>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

Co je Rasalect?<\/h2>\n

Rasalect je peror\u00e1ln\u00ed tableta obsahuj\u00edc\u00ed rasagilin 1 mg<\/strong>. Rasagilin je selektivn\u00ed inhibitor monoaminooxid\u00e1zy typu B (MAO-B)<\/strong> Xadago Azilect<\/strong>. Rasalect je vyr\u00e1b\u011bn ve v\u00fdrobn\u00edm za\u0159\u00edzen\u00ed certifikovan\u00e9m WHO-GMP a je bioekvivalentn\u00ed k origin\u00e1ln\u00ed zna\u010dce ve stejn\u00e9 s\u00edle.<\/p>\n

Rasagilin byl vyvinut jako inhibitor MAO-B druh\u00e9 generace, konkr\u00e9tn\u011b aby se vyhnul amfetaminov\u00fdm metabolit\u016fm selegilinu. M\u00e1 \u010dist\u00fd aktivn\u00ed metabolit (aminoindan), kter\u00fd s\u00e1m o sob\u011b m\u00e1 neuroprotektivn\u00ed vlastnosti v laboratorn\u00edch modelech. Rasagilin m\u016f\u017ee b\u00fdt pou\u017e\u00edv\u00e1n jako monoterapie v \u010dasn\u00e9m st\u00e1diu Parkinsonovy choroby nebo jako dopln\u011bk k levodop\u011b p\u0159i \u00fastupu \u00fa\u010dinku na konci d\u00e1vky.<\/p>\n

Jak funguje Rasalect (rasagilin)?<\/h2>\n

Rasagilin nevratn\u011b deaktivuje MAO-B v mozku, \u010d\u00edm\u017e zpomaluje rozklad dopaminu. Stejn\u011b jako selegilin je selektivn\u00ed pro MAO-B v terapeutick\u00fdch d\u00e1vk\u00e1ch (1 mg\/den), ale ztr\u00e1c\u00ed selektivitu nad 1,5\u20132 mg\/den. Jeho hlavn\u00ed metabolit, aminoindan, m\u00e1 vlastn\u00ed potenci\u00e1ln\u00ed neuroprotektivn\u00ed aktivitu v preklinick\u00fdch modelech \u2014 z\u00e1klad pro studii ADAGIO zam\u011b\u0159enou na modifikaci onemocn\u011bn\u00ed, kter\u00e1 p\u0159inesla nazna\u010duj\u00edc\u00ed, ale ne pr\u016fkazn\u00e9 v\u00fdsledky.<\/p>\n

Srovn\u00e1n\u00ed inhibitor\u016f MAO-B<\/h2>\n

T\u0159i inhibitory MAO-B pou\u017e\u00edvan\u00e9 u Parkinsonovy choroby \u2014 selegilin, rasagilin a safinamid \u2014 sd\u00edlej\u00ed spole\u010dn\u00fd mechanismus \u00fa\u010dinku, ale v\u00fdznamn\u011b se li\u0161\u00ed v metabolitech, d\u00e1vkov\u00e1n\u00ed a klinick\u00e9m vyu\u017eit\u00ed:<\/p>\n\n\n\n\n\n\n\n\n\n
Vlastnost<\/th>\nSelegilin<\/th>\nRasagilin<\/th>\nSafinamid<\/th>\n<\/tr>\n<\/thead>\n
Typick\u00e1 d\u00e1vka<\/td>\n5\u201310 mg\/den<\/td>\n0,5\u20131 mg\/den<\/td>\n50\u2013100 mg\/den<\/td>\n<\/tr>\n
Aktivn\u00ed metabolity<\/td>\nAmphetamin + methamphetamin<\/td>\nAminoindan (neamfetaminov\u00fd)<\/td>\n\u017d\u00e1dn\u00fd stimula\u010dn\u00ed metabolit<\/td>\n<\/tr>\n
\u00da\u010dinek na glutam\u00e1t<\/td>\nNe<\/td>\nNe<\/td>\nAno<\/strong> \u2014 modulace sod\u00edkov\u00fdch kan\u00e1l\u016f\/uvol\u0148ov\u00e1n\u00ed glutam\u00e1tu<\/td>\n<\/tr>\n
Indikace<\/td>\nMonoterapie nebo dopln\u011bk<\/td>\nMonoterapie nebo dopln\u011bk<\/td>\nPouze jako dopln\u011bk<\/strong> \u2014 pro kol\u00edsav\u00fd pr\u016fb\u011bh Parkinsonovy choroby p\u0159i l\u00e9\u010db\u011b levodopou<\/td>\n<\/tr>\n
Riziko nespavosti<\/td>\nVy\u0161\u0161\u00ed (metabolity amfetaminu)<\/td>\nN\u00edzk\u00e1<\/td>\nN\u00edzk\u00e1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Pro koho je Rasalect ur\u010den?<\/h2>\n

Rasalect je vhodn\u00fd pro dosp\u011bl\u00e9 s Parkinsonovou chorobou \u2014 bu\u010f jako monoterapie v ran\u00e9m stadiu onemocn\u011bn\u00ed, nebo jako dopln\u011bk k levodop\u011b u pacient\u016f s motorick\u00fdmi fluktuacemi. Ve srovn\u00e1n\u00ed se selegilinem je rasagilin preferov\u00e1n, pokud je probl\u00e9mem nespavost. Ve srovn\u00e1n\u00ed se safinamidem je rasagilin lep\u0161\u00ed mo\u017enost\u00ed monoterapie (safinamid je schv\u00e1len pouze jako dopln\u011bk).<\/p>\n

D\u00e1vkov\u00e1n\u00ed a pod\u00e1v\u00e1n\u00ed<\/h2>\n

Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9 je 1 mg jednou denn\u011b<\/strong>, u\u017e\u00edvan\u00fd r\u00e1no s j\u00eddlem nebo bez j\u00eddla. Nen\u00ed nutn\u00e1 titrace \u2014 pln\u00fd \u00fa\u010dinek je dosa\u017een b\u011bhem 1\u20132 t\u00fddn\u016f. D\u00e1vky nad 1 mg\/den se obecn\u011b vyh\u00fdbaj\u00ed, proto\u017ee se ztr\u00e1c\u00ed selektivita MAO-B. P\u0159i st\u0159edn\u00edm po\u0161kozen\u00ed jater sn\u00ed\u017eit na 0,5 mg\/den; p\u0159i t\u011b\u017ek\u00e9m po\u0161kozen\u00ed jater se vyvarovat.<\/p>\n\n\n\n\n\n\n\n
Populace<\/th>\nD\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9<\/td>\n1 mg jednou denn\u011b, r\u00e1no<\/td>\n<\/tr>\n
Lehk\u00e9 po\u0161kozen\u00ed jater<\/td>\n0,5 mg jednou denn\u011b<\/td>\n<\/tr>\n
St\u0159edn\u011b t\u011b\u017ek\u00e9 a\u017e t\u011b\u017ek\u00e9 po\u0161kozen\u00ed jater<\/td>\nVyhnout se<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\u26a0 Tyramin a \u201cs\u00fdrov\u00fd efekt\u201d<\/strong> P\u0159i standardn\u00edch d\u00e1vk\u00e1ch selektivn\u00edch k MAO-B nen\u00ed obvykle nutn\u00e1 dietn\u00ed restrikce tyraminu. ne<\/em> Nutn\u00e9. Selektivita MAO-B je v\u0161ak z\u00e1visl\u00e1 na d\u00e1vce \u2014 selegilin nad 10 mg\/den, rasagilin nad 1 mg\/den a safinamid nad 100 mg\/den ztr\u00e1cej\u00ed selektivitu a inhibuj\u00ed tak\u00e9 perifern\u00ed MAO-A. P\u0159i t\u011bchto d\u00e1vk\u00e1ch mohou potraviny bohat\u00e9 na tyramin (zraj\u00edc\u00ed s\u00fdry, uzen\u00e9 maso, bobovit\u00e9 rostliny, fermentovan\u00e1 s\u00f3ja, to\u010den\u00e9 pivo) vyvolat hypertenzn\u00ed krizi. Dodr\u017eujte p\u0159edepsan\u00e9 d\u00e1vkov\u00e1n\u00ed, abyste se tomuto riziku vyhnuli.<\/div>\n

B\u011b\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n

Bolest hlavy (nej\u010dast\u011bj\u0161\u00ed \u2014 obvykle p\u0159echodn\u00e1), artralgie, dyspepsie, deprese, ortostatick\u00e1 hypotenze, p\u0159\u00edznaky podobn\u00e9 ch\u0159ipce. M\u00e9n\u011b \u010dast\u00e9: halucinace, nespavost (mnohem m\u00e9n\u011b ne\u017e u selegilinu), \u00fabytek hmotnosti, p\u00e1dy. S levodopou: zv\u00fd\u0161en\u00e1 dyskineze.<\/p>\n

\u26a0 Serotoninov\u00fd syndrom \u2014 nebezpe\u010dn\u00e9 interakce<\/strong> Kombinace inhibitoru MAO-B se serotonergn\u00edmi l\u00e9ky m\u016f\u017ee zp\u016fsobit serotoninov\u00fd syndrom<\/em>: neklid, pocen\u00ed, t\u0159es, hyperreflexie, hore\u010dka, pr\u016fjem, v t\u011b\u017ek\u00fdch p\u0159\u00edpadech z\u00e1chvaty a smrt. Vyvarujte se:<\/strong> SSRI (fluoxetin, sertralin, paroxetin, citalopram, escitalopram), SNRI (venlafaxin, duloxetin), tricyklick\u00e1 antidepresiva (amitriptylin, imipramin), pethidin (meperidin), tramadol, dextromethorfan, methadon, t\u0159ezalka te\u010dkovan\u00e1, MDMA. Vylu\u010dovac\u00ed obdob\u00ed:<\/strong> p\u0159eru\u0161it u\u017e\u00edv\u00e1n\u00ed fluoxetinu 5 t\u00fddn\u016f p\u0159ed zah\u00e1jen\u00edm inhibitoru MAO-B; ostatn\u00ed SSRI\/SNRI p\u0159eru\u0161it alespo\u0148 2 t\u00fddny p\u0159edem; neza\u010d\u00ednat s fluoxetinem d\u0159\u00edve ne\u017e 2 t\u00fddny po ukon\u010den\u00ed inhibitoru MAO-B.<\/div>\n

Interakce s l\u00e9ky a potravinami<\/h2>\n